Dr. Simon Potter

Position:Principal, Chemical / Life Sciences Leader Australia
Email:simon.potter@spruson.com
Simon Potter

IP Qualifications

Qualification
Registered Australian and New Zealand Patent Attorney
Registered Australian Trade Mark Attorney

Academic Qualifications

QualificationInstitutionYear of Completion
Master of Industrial PropertyUniversity of Technology, Sydney2009
Doctor of Philosophy (PhD)University of Sydney2004
Bachelor of Science (Hons I & University Medal)The University of Sydney/Centenary Institute of Cancer Medicine and Cell Biology2000

Postdoctoral Research Experience

PositionOrganisation/InstitutionDate of Tenure
Postdoctoral FellowInstitut Pasteur (France)2004 - 2006

Fellowships/Memberships/Affiliations

OrganisationLevel
The Institute of Patent and Trade Mark Attorneys of AustraliaMember
The Intellectual Property Society of Australia and New ZealandMember

Selected Patent Cooperation Treaty (PCT) Specifications

PCT Publication NumberTitle of Application
WO2019/028494Multiphasic Tissue Scaffold Constructs
WO2019/000017Intracellular Microrna Signatures of Insulin-producing cells
WO2018/187829Detection Cascades
WO2018/107204Method and apparatus for producing biofuel
WO2018/071954Recombinant microcystin production
WO2018/058172Biooil refining methods
WO2017/011855Biomarker combinations for prostate disease
WO2017/106899Therapeutic methods using erythrocytes
WO2016/074040Non-invasive agent applicator
WO2016/197180Upgrading residues, heavy oils and plastics
WO2016/168885Therapeutic antibodies and uses thereof
WO2016/112423Glypican epitopes and uses thereof
WO2016/149771Streptococcal vaccine
WO2015/106311Cell surface prostate cancer antigen for diagnosis
WO2014/197937Methods for detecting prostate cancer
WO2013/123552Detection of nucleic acids
WO2013/188912Target detection and signal amplification

Selected Publications - Scientific

Scientific Publications
Potter et al. (2007), “Preserved central memory and activated effector memory CD4+ T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study”, J. Virol., 81(24):13904-15
Potter et al. (2006), “Genetic analyses reveal structured HIV-1 populations in serially sampled T lymphocytes of patients receiving HAART”, Virology, 348(1):35-46
Wang, Potter et al. (2005), “Rapid and sensitive detection of severe acute respiratory syndrome coronavirus by rolling circle amplification”, J. Clin. Microbiol., 43(5):2339-44
Seow, Broer, Broer, Bailey, Potter, et al. (2004), “Hartnup disorder is caused by mutations in the neutral amino acid transporter, SLC6A19”, Nature Genetics. 36(9):1003-7
Potter et al. (2004), “HIV-1 Compartmentalization in Diverse Leukocyte Populations During Antiretroviral Therapy”, J. Leuk. Biol., 76(3):562-70
Potter et al. (2003), “Differential cellular distribution of HIV-1 drug resistance in vivo: evidence for infection of CD8+ T cells during HAART”, Virology, 305(2):339-52
Potter et al. (2002), “Hartnup disorder: polymorphisms identified in the neutral amino acid transporter SLC1A5”, J. Inherit. Metab. Dis.,25(6):437-48
Experience and Technical Background

Experienced in the following areas of patent practice:

  • Patent Drafting
  • Local & Foreign Patent Prosecution
  • Patent Oppositions
  • Strategic Advice
  • Patentability Advice
  • Validity & Infringement

Primary patent practice areas by technology:

  • Immunology
  • Vaccines
  • Molecular Biology
  • Stem Cells
  • Virology
  • Diagnostics

Scientific/research background:

A. General technical areas:

  • Immunology
  • Molecular Biology
  • Virology
  • Genetics

B. Honours research:

  • Project investigated whether candidate neutral amino acid transporter gene SLC1A5 is responsible for metabolic disorder Hartnup disease.
  • Used genetic approaches (e.g. linkage analysis) and molecular biology (e.g. sequencing, mutation and expression analysis), with some cell biology.

C. PhD research:

  • Investigated the distribution and mechanisms of antiretroviral drug resistance in various leukocyte populations of HIV+ patients receiving highly active antiretroviral therapy (HAART).
  • Incorporated components of molecular and cellular biology, virology and immunology.
  • Developed a diagnostic assay for the SARS virus using a modified form of rolling circle amplification (RCA).

D. Postdoctoral research:

  • Phenotypic and functional analyses of immune activation and T lymphocyte responses in a cohort of “HIV Controllers.”
  • Immunology with particular emphasis on the cell biology of the immune system HIV controllers showed a preserved CD4+ T(CM)-cell compartment with signs of potent functional activation in the CD4+ T(EM)-cell compartment, but did not show the generalized immune activation pattern associated with disease progression in HIV patients.

Would you like to join the Spruson & Ferguson team?


Work For Us

Contact our Expert Team

Contact Us